Merck Acquires Bio-Techne for $11.3 Billion in Life Sciences Expansion

German pharmaceutical company Merck is acquiring U.S.-based biotech firm Bio-Techne for $11.3 billion, marking its largest acquisition in over a decade and signaling continued consolidation within the life sciences sector.

By Jamie Wilde Fri, June 26, 2026 at 7:01 AM GMT+3 3 min read · Yahoo Finance · June 26, 2026, 04:01 UTC

Merck Acquires Bio-Techne for $11.3 Billion in Life Sciences Expansion

Tickers: $MRK $TECH

Topics: biotech corporate_strategy life_sciences pharmaceuticals

Read the full article at Yahoo Finance

More World news

Joe Lavis Named to D CEO's 2027 Dallas 500 List PR Newswire · November 12, 2026, 16:26 UTC
Sanmina Corporation (SANM) Shares Rise 8% Amid Five-Day Winning Streak Seeking Alpha · November 12, 2026, 16:23 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal and National Security Concerns Motley Fool · November 12, 2026, 16:17 UTC
Citigroup Lowers Nvidia Price Target Following Jensen Huang's Departure Motley Fool · November 12, 2026, 16:19 UTC
The General Insurance and WWE Partner with Second Harvest Food Bank to Combat Food Insecurity in Nashville PR Newswire · November 12, 2026, 16:21 UTC
Fennec Pharmaceuticals Reports Record Q3 2026 Results with Significant EBITDA Growth Motley Fool · November 12, 2026, 16:11 UTC
Rockwell Medical Reports Q3 2026 Results and Announces Vantive Limited Acquisition Motley Fool · November 12, 2026, 16:11 UTC
BioHarvest Sciences Reports Q3 2026 Financial Results Amid Strategic Shift to Fragrance Development Motley Fool · November 12, 2026, 16:11 UTC
Xunlei Reports Q3 2026 Revenue Growth Amid Increased Operating Losses and Investment Adjustments Motley Fool · November 12, 2026, 16:11 UTC
Sandisk Shares Decline Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 16:14 UTC